By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Origen Therapeutics, Inc. 

5885 Hollis Street

Emeryville  California  94608  U.S.A.
Phone: 510-597-5100 Fax: n/a



Start Up

Company News
Genavia Therapeutics Licenses Technology from Origen Therapeutics, Inc. for Cost-Efficient Production of Human Therapeutics in Chicken Eggs 3/9/2009 9:31:57 AM
Symphogen A/S And Origen Therapeutics, Inc. Collaborate to Produce Transgenic Chicken for Generation of Fully Human Antibody Therapeutics 3/6/2009 10:12:59 AM
Origen Therapeutics, Inc. Announces Change In Chief Financial Officer And Reports Naked Short Selling To SEC 10/6/2008 11:19:56 AM
Origen Therapeutics, Inc. Appoints Phil Leighton as Director of Research and Announces Departure of Robert Etches, VP of Research 6/23/2008 8:50:37 AM
Origen Therapeutics, Inc. Receives $2 Million ATP Grant to Advance Technology for Discovery and Production of Human Polyclonal Antibodies from Transgenic Chickens 10/3/2007 10:16:19 AM
Chickens Genetically Altered To Pass On Inserted Trait 6/8/2006 1:29:28 PM
Origen Therapeutics, Inc. Publishes In Nature A Robust And Versatile Method For Creating Transgenic Chickens 6/8/2006 12:47:47 PM
New Chicken Gene-Transfer System Holds Promise For Research And Industry 6/7/2006 1:21:09 PM
Origen Therapeutics, Inc. Receives SBIR Grant Aimed At Furthering Human Polyclonal Antibody Development In Chickens; Over $5 Million10/19/2005 5:10:02 PM
First Production Of Human Monoclonal Antibodies In Chicken Eggs Published In Nature Biotechnology10/19/2005 5:09:11 PM